

Product Data Sheet

Product Name: DOTA-LM3

Cat. No.: GC74393

Chemical Properties

Cas. No. 1192362-32-5

Formula $C_{69}H_{93}ClN_{16}O_{19}S_2$

M.Wt 1550.16


Solubility

Storage Sealed storage, away from moisture and light

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH₂, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as ¹⁷⁷Lu-DOTA-LM3 and ⁶⁸Ga-DOTA-LM3. ⁶⁸Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. ¹⁷⁷Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

^{177}Lu -DOTA-LM3 is tolerated. ^{177}Lu -DOTA-LM3 in the whole body and in the kidneys, spleen, and metastases, resulting in higher mean absorbed organ and tumor doses[2].

References:

- [1]. Zhu W, et al. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of ^{68}Ga -NODAGA-LM3 and ^{68}Ga -DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with ^{68}Ga -DOTATATE. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1613-1622.
- [2]. Baum RP, et al. First-in-Humans Study of the SSTR Antagonist ^{177}Lu -DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. J Nucl Med. 2021 Nov;62(11):1571-1581.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA